Merck reveals positive results from KEYTRUDA® Plus Phase 3 trial
Category: #health  By Pankaj Singh  Date: 2019-10-01
  • share
  • Twitter
  • Facebook
  • LinkedIn

Merck reveals positive results from KEYTRUDA® Plus Phase 3 trial

Breast cancer is initiated when genes regulating cell growth mutate. These mutations allows the cells to divide and multiply rampantly and are formed in the ducts or lobules of the breast. Several pharmaceutical firms are developing novel treatments to effectively treat this prevailing disease.

Merck & Co., Inc., is one such firm based in New Jersey that recently announced clinical results from its neoadjuvant/adjuvant KEYNOTE-522 Phase 3 trial assessing KEYTRUDA, the pharmaceutical’s anti-PD-1 therapy targeted towards patients with early-stage TNBC (triple-negative breast cancer).

According to reports, the trial investigated a regimen of neoadjuvant KEYTRUDA followed by adjuvant KEYTRUDA as monotherapy. Moreover, interim findings from the first randomized trial of an anti-PD-1 therapy for TNBC were been presented at the European Society for Medical Oncology (ESMO) 2019 Congress.

Speaking on the announcement, Dr. Roger M. Perlmutter, President, Merck Research Laboratories, said that this trial is first to deploy a combined adjuvant and neoadjuvant treatment with KEYTRUDA in patients with early-stage TNBC. He said that the results of the KEYNOTE-522 study are very encouraging and indicate the potential of the drug to change the treatment of patients diagnosed with TNBC.

As for Dr. Peter Schmid, lead at the Centre for Experimental Cancer Medicine, Barts Cancer Institute, there is a significant need for novel treatment regimens that could increase the pCR rates in this patient population and the KEYTRUDA plus chemotherapy in the neoadjuvant setting and the positive trend for event free-survival demonstrated in this trial could significantly help improve pCR rates.

Prior to this announcement, Merck had revealed that the European Commission has approved KEYTRUDA, as the first-line treatment for patients suffering from advanced RCC (renal cell carcinoma). Apparently, the approval was based on the findings from the Phase 3 KEYNOTE-426 trial, which revealed that KEYTRUDA, along with axitinib, reduced the risk of death by 47% compared with sunitinib in patients with advanced RCC.

Source Credit: https://www.mrknewsroom.com/news-release/oncology/mercks-keytruda-pembrolizumab-plus-chemotherapy-showed-statistically-significa



About Author

Pankaj Singh

Email: [email protected]   

Pankaj Singh

Pankaj Singh Develops content for Market Size Forecasters, Algosonline, and a couple of other platforms. A Post Graduate in Management by qualification, he worked as an underwriter in the UK insurance domain before deciding to switch his field of profession. With exp...

Read More

More News By Pankaj Singh

Anova Enterprises expands AnovaOS™ to boost clinical development
Anova Enterprises expands AnovaOS™ to boost clinical development
By Pankaj Singh

The U.S-based Anova Enterprises, Inc. (Anova) has reportedly expanded the AnovaOS™ technology platform in order to boost the development of promising novel treatments. The platform brings pharmaceutical companies...

Serum Institute to Resume Oxford COVID-19 Vaccine’s Trail in India
Serum Institute to Resume Oxford COVID-19 Vaccine’s Trail in India
By Pankaj Singh

India’s Drugs Controller General (DCGI) has approved Pune-based Serum Institute of India (SII) to restart the clinical trial of the Oxford/AstraZeneca COVID-19 vaccine in India.

Everest Medicines Announces Cefepime-Taniborbactam Phase 1 Results

Everest Medicines Announces Cefepime-Taniborbactam Phase 1 Results
By Pankaj Singh

Everest Medicines announced the top-line results from the Phase 1 clinical trial of Taniborbactam with cefepime for treating infections caused by multi-drug resistant pathogens in China. Everest Medicines is a biopharm...